口服生技藥品市場：依藥物類別、適應症、依配銷通路、按地區

Oral Biologics Market, By Drug Class, By Disease Indication (Diabetes, Hyperoxaluria, Acromegaly, Irritable Bowel Syndrome & Chronic Idiopathic Constipation, Others ), By Distribution channel, By Geography

出版日期: 2023年08月31日 | 出版商:

Coherent Market Insights | 英文 197 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2023 年，全球口服生技藥品市場規模將達到 26.2 億美元，預計在預測期內（2023-2030 年）年複合成長率為 35.4%。

報告範圍		報告詳情
基準年	2022年	2023年市場規模	26.2億美元
實績資料	2018-2021	預測期	2023-2030
預測期年複合成長率	35.40%	2030年市場規模預測	218.4億美元

口服生技藥品全球市場佔有率(%)（以藥物類型），2023 年

口服生技藥品是指具有生物來源的一類藥物，例如蛋白質或抗體，並且給藥口服（以錠劑或膠囊的形式）而不是透過注射給藥。由於其具有改變各種治療領域的治療格局的潛力，該領域正在吸引大量關注和投資。口服生技藥品的潛在用途涵蓋廣泛的治療領域。類風濕性關節炎、發炎性腸道疾病疾病和多發性硬化症等自體自體免疫疾病是主要目標之一。此外，口服生技藥品還有望治療糖尿病、癌症和罕見遺傳疾病。這種用途吸引了製藥巨頭和新興企業的關注，形成了促進市場創新和協作的競爭形勢。此外，患者便利性和技術進步使口服生技藥品成為傳統注射生技藥品的有前途的替代品，預計將在預測年度內推動市場成長。

市場動態

主要市場參與企業正專注於在市場上推出新產品，以擴大其全球業務，預計這將在預測期內推動市場成長。例如，2022年1月，全球製藥公司諾和諾德推出了口服錠劑GLP-1受體類似物（GLP-1 RA），用於治療糖尿病。在口服 GLP-1 受體類似物 (GLP-1 RA)錠劑發布之前，GLP-1 受體類似物 (GLP-1 RA) 僅以注射劑形式提供。 GLP-1 RA從未被製成口服藥物。口服索馬魯肽是GLP-1RA索馬魯肽和吸收促進劑SNAC的複合製劑，可防止其像其他胜肽一樣在胃中分解並改善吸收。

本研究的主要特點

本報告詳細分析了全球口服生技藥品市場，並提供了以2022年為基準年的預測期（2023-2030）的市場規模和年複合成長率(CAGR)。它揭示了各個細分市場的潛在商機，並解釋了市場有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要考察。
它根據公司亮點、產品系列、主要亮點、財務實績和策略等參數，介紹了全球口服生技藥品市場的主要企業。
該報告的見解將使行銷人員和公司負責人能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出資訊的決策。
口服生技藥品全球市場報告迎合了該行業的各種相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
相關人員可以透過分析全球口服生技藥品市場時所使用的各種策略矩陣來促進決策。

Report Coverage	Report Details
Base Year:	2022	Market Size in 2023:	US$ 2.62 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	35.40%	2030 Value Projection:	US$ 21.84 Bn

Oral biologics refers to a category of medications that are biologically derived, like proteins or antinodies, and are administered orally (in the form of pills and capsules) rather than through injections. This segment has garnered significant attention and investment due to its potential to revolutionize the treatment landscape across various therapeutic areas. The potential applications of oral biologics span a wide range of therapeutic areas. Autoimmune disorders, including rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis, are among the prominent targets. Additionally, oral biologics hold promise for treating diabetes, cancer, and rare genetic diseases. This versatility has attracted attention from both pharmaceutical giants and innovative startups, fostering a competitive landscape that drives innovation and collaboration in the market. Further, patient convenience and technological advancements have positioned oral biologics as a promising alternative to traditional injectable biologics, which is expected to drive market growth in the forecast years.

Market Dynamics

The key market players are focused on the launch of new products in the market to expand their business globally, and this is expected to boost the growth of the market over the forecast period. For instance, in January 2022, Novo Nordisk, a global pharmaceutical company, launched the GLP-1 receptor analogue (GLP-1 RA) in an oral pill formulation for the treatment of diabetes. Before the launch of the GLP-1 receptor analogue (GLP-1 RA) oral pill, GLP-1 receptor analogue (GLP-1 RA) was only available in injection form. A GLP-1 RA has never before been created in an oral formulation. In order to prevent it from degrading in the stomach like other peptides do and to improve absorption, oral semaglutide is a co-formulation of GLP-1RA semaglutide and the absorption enhancer SNAC.

Key features of the study:

This report provides an in-depth analysis of the global oral biologics market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global oral biologics market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, Inc., Rani Therapeutics, Entera Bio Ltd., AbbVie Inc., Enteris BioPharma, Inc., Chiasma, Inc. and Allena Pharmaceuticals, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global oral biologics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global oral biologics market.

Oral Biologics Market Detailed Segmentation:

By Drug Class:
- Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
- Hormone
- Recombinant Enzyme
- Guanylate Cyclase-C Agonist
- Somatostatin Analogue
- Others
By Disease Indication:
- Diabetes
- Hyperoxaluria
- Acromegaly
- Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
- Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
By Distribution channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Company Profiles
- Novo Nordisk A/S
- Biocon Limited
- Oramed Pharmaceuticals, Inc.
- Rani Therapeutics
- Entera Bio Ltd.
- AbbVie Inc.
- Enteris BioPharma, Inc.
- Chiasma, Inc.
- Allena Pharmaceuticals, Inc.

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Disease Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Test Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis

4. Global Oral Biologics Market-COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Oral Biologics Market, By Drug Class, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Hormone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Recombinant Enzyme
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Guanylate Cyclase-C Agonist
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Somatostatin Analogue
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends

6. Global Oral Biologics Market, By Disease Indication, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Hyperoxaluria
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Acromegaly
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends

7. Global Oral Biologics Market, By Distribution Channel, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

8. Global Oral Biologics Market, By Region, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
North America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Disease Indication, 2018-2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Bn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Disease Indication, 2018-2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Bn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Disease Indication, 2018-2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Bn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Disease Indication, 2018-2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Bn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Disease Indication, 2018-2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Bn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Disease Indication, 2018-2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country/Region, 2018-2030, (US$ Bn)
North Africa
Central Africa
South Africa